Skip to main content
. 2022 Aug 3;13(4):e01527-22. doi: 10.1128/mbio.01527-22

FIG 4.

FIG 4

Intranasal administration of ACT-neutralizing antibody protects mice against lethal pertussis challenge. (A) BALB/c mice (n = 6 per group; half female; 32 days old) were administered 10 μg M2B10 or an isotype control antibody intranasally (i.n.) or M2B10 intraperitoneally (i.p.) 2 h prior to challenge with a high dose (2 × 108 CFU) of B. pertussis TohamaI. All antibodies were produced with mouse IgG2a/kappa constant domains. (B) Five micrograms of M2B10, 10 μg of the isotype control, or the PBS control was administered intranasally to 32-day-old BALB/c mice (n = 6; half female) before infection with 2 × 108 CFU B. pertussis TohamaI. (C) Antibodies M2B10 and M1F5 and their aglycosylated N297A counterparts (10 μg M2B10, 10 μg M2B10-N297A, 20 μg M1F5, and 20 μg M1F5-N297A) were administered intranasally to mice (n = 5) before infection with 2 × 108 CFU B. pertussis TohamaI. For all panels, *** indicates a P value of <0.001 as determined by the Mantel-Cox test with a Bonferroni-Dunn posttest for multiple comparisons.